Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS-7058 + adebrelimab + BP102
- Development stage
- Unknown
- Lead developer
- Shandong Suncadia Medicine
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
HRS-7058 + SHR-1316 + BP102 is an investigational triple combination regimen being developed by Jiangsu Hengrui Pharmaceuticals (via its subsidiary Shandong Suncadia Medicine) for the treatment of advanced malignant solid tumors, particularly those harboring KRAS G12C mutations. The regimen consists of HRS-7058, a small molecule inhibitor targeting the oncogenic KRAS G12C mutation; adebrelimab (SHR-1316), a humanized IgG4 monoclonal antibody that acts as an immune checkpoint inhibitor by targeting PD-L1; and BP102, a biosimilar of the anti-angiogenic monoclonal antibody bevacizumab which targets VEGF. This combination is designed to simultaneously inhibit tumor cell signaling, enhance anti-tumor immune responses, and suppress tumor-associated angiogenesis. It is currently being evaluated in Phase II clinical trials to assess safety, tolerability, and efficacy.
- Other names
- HRS-7058 + SHR-1316 + BP102
02
Targets
KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on HRS-7058 + adebrelimab + BP102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS-7058 + adebrelimab + BP102.